Evidence map›Paper›PMID 40933937›Full record

ReviewWorld journal of clinical cases2025

Mini-review on insulin resistance assessment: Advances in surrogate indices and clinical applications.

Kengo Moriyama

Abstract readReview
In one paragraph

Review in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kengo MoriyamaDepartment of Clinical Health Science, Tokai University School of Medicine, Hachioji 1920032, Tokyo, Japan. kengomoriyama@tokai.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance (IR) is widely recognized as a key contributor to metabolic disorders, and various surrogate indices have been developed to estimate IR in clinical and research settings. The hyperinsulinemic-euglycemic clamp is considered the gold standard method for assessing insulin resistance due to its precision; however, its complexity limits its widespread clinical application. Consequently, surrogate indices derived from fasting and post-load glucose and insulin levels have been developed to estimate IR, facilitating early detection and risk stratification in metabolic disorders. This mini-review discusses the clinical utility, strengths, and limitations of key IR indices, including the homeostasis model assessment of IR, quantitative insulin sensitivity check index, Matsuda index, and triglyceride-glucose index. Overall, the evidence presented to date suggests that these indices provide valuable estimates of IR in various populations. Yet, their applicability varies depending on ethnic background, disease status, and clinical setting. Integrating these indices into routine clinical practice and research could improve metabolic risk assessment and guide preventive interventions. Further investigations are necessary to refine their accuracy and determine optimal cut-off values for various populations.

Indexed as

Cardiovascular diseaseDiabetesHomeostasis model assessment of insulin resistanceInsulin resistanceMatsuda indexMetabolic disordersQuantitative insulin sensitivity check indexRisk assessmentSurrogate markersTriglyceride-glucose index

Identifiers

PMID40933937
PMCPMC12417990

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.